头孢他啶-阿维巴坦挽救性治疗产肺炎克雷伯菌碳青霉烯酶肺炎克雷伯菌感染患者的疗效
回顾性分析意大利138例接受头孢他啶-阿维巴坦(CAZ-AVI)挽救治疗的产肺炎克雷伯菌碳青霉烯酶肺炎克雷伯菌(KPC-Kp)感染成人患者。感染后30天死亡47例(34.1%);104例菌血症患者30天死亡率为36.5%,显著低于匹配对照组的55.8%(P=0.005)。CAZ-AVI似乎是治疗严重KPC-Kp感染的有前景药物,尤其是菌血症患者。
要点
- 138例KPC-Kp感染患者接受CAZ-AVI挽救治疗,30天死亡47例(34.1%)。
- 104例菌血症患者30天死亡率36.5%,低于匹配对照组55.8%(P=0.005)。
- 208例菌血症多因素分析中,接受CAZ-AVI是生存的唯一独立预测因素。
核心结论
- CAZ-AVI似乎是治疗严重KPC-Kp感染的有前景药物,尤其是涉及菌血症者。
研究设计与样本
- 回顾性综述138例在意大利同情用药项目中接受CAZ-AVI的成人KPC-Kp感染病例。
- 分析病例特征与结局,并在菌血症大亚组中专门探讨生存。
主要发现
- 138例患者在一线其他抗菌药物治疗(中位7天)后开始CAZ-AVI挽救治疗。
- CAZ-AVI与至少1种其他有活性抗生素联用于109例(78.9%)。
- 感染发生后30天,138例中47例(34.1%)死亡。
- 104例菌血症KPC-Kp感染患者30天死亡率为36.5%,匹配对照组为55.8%(P=0.005)。
- 208例KPC-Kp菌血症多因素分析:脓毒性休克、中性粒细胞减少、Charlson合并症指数≥3、近期机械通气为死亡独立预测因素,接受CAZ-AVI是生存的唯一独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for the treatment of complicated intra-abdominal and urinary tract infections, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options. CAZ-AVI displays in vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme producers, but clinical trial data on its efficacy in this setting are lacking. METHODS: We retrospectively reviewed 138 cases of infections caused by KPC-producing K. pneumoniae (KPC-Kp) in adults who received CAZ-AVI in compassionate-use programs in Italy. Case features and outcomes were analyzed, and survival was then specifically explored in the large subcohort whose infections were bacteremic. RESULTS: The 138 patients started CAZ-AVI salvage therapy after a first-line treatment (median, 7 days) with other antimicrobials. CAZ-AVI was administered with at least 1 other active antibiotic in 109 (78.9%) cases. Thirty days after infection onset, 47 (34.1%) of the 138 patients had died. Thirty-day mortality among the 104 patients with bacteremic KPC-Kp infections was significantly lower than that of a matched cohort whose KPC-Kp bacteremia had been treated with drugs other than CAZ-AVI (36.5% vs 55.8%, P = .005). Multivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index ≥3, and recent mechanical ventilation as independent predictors of mortality, whereas receipt of CAZ-AVI was the sole independent predictor of survival. CONCLUSIONS: CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia.
引用
- Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019. PMID: 29893802. doi:10.1093/cid/ciy492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。